CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

VPM1002Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1142 IC14 Wiki 0.58
drug1647 Normobaric oxygen therapy Wiki 0.58
drug1137 Hyperbaric oxygen therapy Wiki 0.58
drug1822 Placebo Wiki 0.10

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D012141 Respiratory Tract Infections NIH 0.24
D003141 Communicable Diseases NIH 0.10
D007239 Infection NIH 0.07

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0011947 Respiratory tract infection HPO 0.24

There are 3 clinical trials

Clinical Trials

1 A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System

The aim of this study is to investigate whether vaccination of healthcare professionals with VPM1002 could reduce the number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection). VPM1002 is a vaccine that is a further development of the old Bacillus Calmette-Guérin (BCG) vaccine, which has been used successfully as a vaccine against tuberculosis for about 100 years, especially in developing countries. VPM1002 has been shown in various clinical studies to be significantly safer than the BCG vaccine. VPM1002 strengthens the body's immune defence and vaccination with BCG reduces the frequency of respiratory diseases. It is therefore assumed that a VPM1002 vaccination could also provide (partial) protection against COVID-19 disease caused by the new corona virus "SARS-CoV 2". A total of 1200 health care professionals (doctors, nurses and paramedical staff) with high expected exposure to SARSCoV-2 infected patients will receive a single dose of either VPM1002 or Placebo. All subjects will be requested to enter data regarding absenteeism, adverse events / serious adverse events, hospitalizations, intensive care unit admissions into an online questionnaire.

NCT04387409 Infection, Respiratory Tract Biological: VPM1002 Biological: Placebo
MeSH:Respiratory Tract Infections
HPO:Respiratory tract infection

Primary Outcomes

Measure: Number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection)

Time: From day 0 to day 240

Secondary Outcomes

Measure: Cumulative incidence of documented SARS-CoV-2 infection

Time: From day 0 to day 240

Measure: Number of days absent from work due to documented SARS-CoV-2 infection

Time: From day 0 to day 240

Measure: Number of days absent from work due to exposure to person with documented SARS-CoV-2 infection

Time: From day 0 to day 240

Measure: Number of days absent from work due to symptoms of respiratory disease, documented SARS-CoV-2 infection, or fever (≥ 38 °C)

Time: From day 0 to day 240

Measure: Number of days of self-reported fever (≥ 38 °C)

Time: From day 0 to day 240

Measure: Number of days of self-reported acute respiratory symptoms

Time: From day 0 to day 240

Measure: Cumulative incidence of self-reported acute respiratory symptoms

Time: From day 0 to day 240

Measure: Cumulative incidence of death for any reason

Time: From day 0 to day 240

Measure: Cumulative incidence of death due to documented SARS-CoV-2 infection

Time: From day 0 to day 240

Measure: Cumulative incidence of ICU admission for any reason

Time: From day 0 to day 240

Measure: Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection

Time: From day 0 to day 240

Measure: Cumulative incidence of hospital admission for any reason

Time: From day 0 to day 240

Measure: Cumulative incidence of hospital admission due to documented SARS-CoV-2 infection

Time: From day 0 to day 240

2 A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System

The aim of this study is to investigate whether vaccination of elderly with VPM1002 could reduce hospital admissions and/or severe respiratory infectious diseases in the SARS-CoV-2 pandemic . VPM1002 is a vaccine that is a further development of the old Bacillus Calmette-Guérin (BCG) vaccine, which has been used successfully as a vaccine against tuberculosis for about 100 years, especially in developing countries. VPM1002 has been shown in various clinical studies to be significantly safer than the BCG vaccine. VPM1002 strengthens the body's immune defence and vaccination with BCG reduces the frequency of respiratory diseases. It is therefore assumed that a VPM1002 vaccination could also provide (partial) protection against COVID-19 disease caused by the "new corona virus" SARS-CoV 2.

NCT04435379 Infection, Respiratory Tract Biological: VPM1002 Biological: Placebo
MeSH:Communicable Diseases Infection Respiratory Tract Infections
HPO:Respiratory tract infection

Primary Outcomes

Measure: Number of days with severe respiratory disease at hospital and/or at home

Time: From day 0 to day 240

Secondary Outcomes

Measure: Cumulative incidence of hospital admissions

Time: From day 0 to day 240

Measure: Cumulative incidence of documented SARS-CoV-2 infection

Time: From day 0 to day 240

Measure: Number of days with self-reported fever (≥ 38 ºC)

Time: From day 0 to day 240

Measure: Number of days with self-reported acute respiratory symptoms

Time: From day 0 to day 240

Measure: Cumulative incidence of self-reported acute respiratory symptoms

Time: From day 0 to day 240

Measure: Cumulative incidence of death for any reason

Time: From day 0 to day 240

Measure: Cumulative incidence of death due to documented SARS-CoV-2 infection

Time: From day 0 to day 240

Measure: Cumulative incidence of ICU admission for any reason

Time: From day 0 to day 240

Measure: Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection

Time: From day 0 to day 240

Measure: Cumulative incidence of hospital admission due to documented SARSCoV- 2 infection

Time: From day 0 to day 240

3 A Randomized, Double-blind, Placebo-controlled Phase 3 Study: Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity

Bacille Calmette-Guerin (BCG) is a live attenuated vaccine administered for prevention of tuberculosis. Recently, several groups have hypothesized that BCG may "train" the immune system to respond to a variety of unrelated infections, including viruses and in particular the coronavirus responsible for COVID-19. Trials are currently being conducted in Australia, Netherlands, Germany and the United Kingdom to evaluate its effectiveness. Front line workers includes members of municipal and provincial police services, emergency medical personnel, firefighters, public transport employees, health service workers and food manufacturing employees. They are at high risk of infection from COVID-19, with potentially high infection rate. The investigators propose an interventional trial to evaluate the effectiveness of BCG vaccination to prevent COVID-19 infection and reduce its severity in front-line employees in Ontario.

NCT04439045 SARS-CoV-2 Infection Biological: VPM1002 Other: Placebo
MeSH:Infection Communicable Diseases

Primary Outcomes

Description: To compare the self-reported incidence of SARS-CoV-2 infection (confirmed by positive test) following vaccination with either VPM1002 or placebo.

Measure: COVID-19 infection

Time: 7 months

Secondary Outcomes

Description: Compare the incidence of hospitalization in participants with positive COVID-19 test treated with either VPM1002 or placebo

Measure: Incidence of hospitalization for COVID-19

Time: 7 months

Description: Compare the incidence of hospitalization requiring intensive care (ICU admission) in participants with positive COVID-19 test treated with either VPM1002 or placebo

Measure: Incidence of ICU admission for COVID-19

Time: 7 months

Description: Compare the incidence of acute respiratory distress syndrome (ARDS) in participants with positive COVID-19 test treated with either VPM1002 or placebo.

Measure: Incidence of ARDS

Time: 7 months

Description: Compare the incidence of the need for mechanical ventilation in participants with positive COVID-19 test treated with either VPM1002 or placebo.

Measure: Mechanical ventilation for COVID-19

Time: 7 months

Description: To compare the incidence of secondary infection in participants with positive COVID-19 test treated with either VPM1002 or placebo.

Measure: Secondary infection in COVID-19

Time: 7 months

Description: To compare the mortality in participants with positive COVID-19 test treated with either VPM1002 or placebo.

Measure: COVID-19-related Mortality

Time: 7 months

Description: Compare the incidence of deep vein thrombosis, pulmonary embolism, or stroke in participants with positive COVID-19 test treated with either VPM1002 or placebo.

Measure: Incidence of DVT

Time: 7 months

Other Outcomes

Description: Compare the incidence of COVID-19 in participants who have received BCG vaccination previously.

Measure: Incidence of COVID-19 in Participants with Past BCG Vaccination

Time: 7 months

Description: To measure cardiac troponin, B-type natriuretic peptide, N-terminal pro b-type natriuretic peptide, C reactive protein, serum amyloid A, and procalcitonin identified as potential biomarkers of COVID-19 infection using blood samples collected prior to the vaccination and at the end of the 7-month follow-up.

Measure: Measure cardiac troponin, B-type natriuretic peptide, N-terminal pro b-type natriuretic peptide, C reactive protein, serum amyloid A, and procalcitonin as biomarkers of COVID-19

Time: 7 months

Description: Adverse events following administration of VPM1002 when used for prevention of COVID-19.

Measure: Adverse events following BCG vaccine

Time: 7 months

Description: To evaluate the ability of the VPM1002 vaccine to prime an innate trained immunity (i.e. inducing Th1 and Th17 responses to unrelated stimuli) compared to participants administered placebo.

Measure: Innate Trained Immunity

Time: 7 months

Related HPO nodes (Using clinical trials)

HP:0011947: Respiratory tract infection
Genes 664
CCDC39 KMT2D RSPH1 DOCK8 NKX2-1 CCNO SPAG1 LIMK1 MPLKIP RAG1 DSG1 BIRC3 ELP1 TSC2 IL17F BLNK BACH2 SGSH IKBKB CD79A AFF4 ARID1B TNFRSF13C CD19 DNAH1 MYO5A AICDA NOTCH3 ELN LAMTOR2 NADK2 CTLA4 DPM2 PWAR1 GATA6 SFTPC FOXN1 MESP2 ELANE CD81 PNP MED25 ZAP70 RAG2 WRAP53 DNAAF1 STAT3 ATM LTBP3 CLCA4 DNAH9 BTK RSPH3 TERT TYK2 LRBA RSPH4A SOX11 RYR1 TNNT2 SMARCD2 GAS8 SLC5A7 KIF1A ROR2 NCF4 COLQ TNFRSF13B HLA-B CCDC65 COL11A2 ORC6 DCLRE1C CTLA4 CACNA1C GBA RNF113A ICOS SETBP1 CYBC1 MGP VPS33A COL13A1 MYSM1 DNAAF4 FLI1 MECP2 MAN2B1 HLA-DQA1 SCNN1A GLB1 IL21R CSF2RB SELENON INPPL1 CD3G ACADVL COL6A3 NSMCE3 AGA CCDC65 HGSNAT AP3D1 NFIX EXOSC9 RAG2 KIAA0586 FCGR2A ABCA12 NFKB2 TFRC NDN MAPK1 LAMA2 NCF4 ARSB LYST RAG1 TPP2 TGFB1 INPPL1 RAG2 TNFSF11 XIAP UNG SCNN1A DNAAF6 SCN10A IL2RG CCDC103 CLCN7 IGHM GNPTAB DNAAF4 CXCR4 PLEC HLA-DPB1 OCRL RFXAP SCN11A CFB TNNI3 TINF2 DCLRE1C MAGEL2 TAF1 SCNN1B CARD11 USB1 GTF2IRD1 CCDC103 SNORD115-1 IL2RG HLA-DQB1 TBC1D23 DLL3 RFXANK MYO9A SCNN1G CD79A ICOS RFC2 TAP1 CD3D FOXJ1 AGRN PIK3R1 WIPF1 RSPH4A IL2RG ACTA1 SRP54 RPGR SNAP25 TSC1 CORO1A IRF8 NCF2 GAS8 ZNHIT3 FOXP1 EP300 JAGN1 ZBTB24 TGFB1 TNFRSF13B CD3E DNAL1 EXTL3 NCF1 SNRPN B2M CLIP2 SCNN1G SFTPC LRRC56 WAS RMRP FUCA1 RSPH9 PEX13 GATA4 CFI ERCC3 FOXP1 ITGA3 PCGF2 TNFRSF13C ATP6V0A2 DNMT3B LEP BCR ZBTB24 NELFA RNF125 NECTIN1 EPM2A TGM1 CCDC40 JAK3 NEK10 MYPN RAC1 CREBBP DNAI2 PLG DDR2 UGP2 NME8 COL6A1 SLC25A1 ECM1 CD3E NFKBIA IGLL1 CHRM3 PRTN3 COG6 CD8A STX1A DNAI1 CYBB IDUA GSN EPG5 TCIRG1 DNAJB13 EDARADD TERT CR2 SOX4 NSD2 GAA TARS1 LEPR ELP1 ALMS1 IL2RB SULT2B1 RAG2 SLC25A24 SMPD1 WDR19 CHAMP1 DNAJB13 FOXP3 RNU4ATAC PLP1 ARID1A CFAP410 BTK TCTN3 RFXANK MYH3 FCN3 SMARCE1 ALPL SLC18A3 IL17RA NR2F2 NKX2-1 SCNN1G CCBE1 SLC52A3 PWRN1 DCLRE1C RYR1 AGA CIITA CR2 LRRC6 PIGN CFAP298 DNAAF5 CCNO BLM CFTR NCF1 CR2 IL2RA LCK UMPS USP9X CD3D ARID2 RUNX2 SLC35C1 TIMM8A NGLY1 NFKB2 CCDC114 TPM3 SCNN1B ADA LRRC56 PEPD IPW KATNIP LYST GRHL3 CCDC151 NBN SYT2 SPAG1 PRKCD LAMB2 CTC1 PMM2 DNAAF3 FLNC DNAAF1 POLR3A LIPN STAT1 TECPR2 SCNN1B RAG1 SDR9C7 ASAH1 DNAAF6 CRELD1 MYSM1 OSTM1 GBA CYBA RNU4ATAC COL13A1 VAMP1 MGP SMARCC2 MCIDAS G6PC3 IL17RC PSAP KAT6B PIK3R1 CD81 SLC1A4 NOP10 NGLY1 MANBA SHROOM4 ALB SMARCD1 SCNN1A CD19 ALMS1 GUSB TTC25 SMN1 RIPK1 UNC119 IGHM CD79B CFAP221 SAMD9 CYP4F22 GTF2H5 GLI3 IGLL1 SLC29A3 RPGR SCNN1B STK36 PLOD1 DNAAF5 GMNN RAG1 GNS COL11A2 OFD1 TNFRSF11A MALT1 NFE2L2 CD19 DCTN4 COG4 SCNN1A CD40LG NME8 SELENON ADNP CFTR NPAP1 CFTR DOCK8 CFAP298 SMPD1 RAG1 P4HTM MAN2B1 SLC26A2 CFAP300 RAB3GAP2 ALG12 JAK3 GTF2E2 IL21 BCL10 NRAS PRKDC TNFRSF13C SH3KBP1 ZNF341 NXN RSPH9 RFXAP SPEF2 MSN LIG4 MCM4 TBCE GALNS SLC12A6 NIPBL STAT3 ZMYND10 IL7R NAGLU HELLS CTSC NIPAL4 RASGRP1 SMARCB1 SP110 LETM1 RSPH1 CCDC39 ARMC4 LAMTOR2 TNFRSF1A IKZF1 IKBKB DNAI2 MBTPS2 FBLN5 ACP5 PTPRC NFKB2 ZAP70 TPM2 TCIRG1 NEK10 ARMC4 MS4A1 MTHFD1 CARMIL2 UBE2A EGFR RYR1 ADA DNAI1 PLCG2 PTPN22 DNMT3B BAZ1B TAPBP RTEL1 ABCA12 SNX10 CSF2RA MESP2 SMARCA4 AK2 DNAH11 KCNJ6 HACD1 DCLRE1C SAMD9L PNP ITGA7 ALOXE3 HLA-DPA1 HERC2 SLC46A1 LRRC8A IER3IP1 TSC2 TGFB1 TRAF3IP2 HPS6 ADA ICOS FLNA TRIP4 FMO3 DPF2 GFI1 ARID1B IRAK4 MKRN3-AS1 VPS33A DNAAF2 NOTCH2 SFTPA2 PCNT CRLF1 ELANE DNAH5 NFKB1 PANK2 GBA GAS2L2 GTF2I CD247 STAT1 RAG2 CCDC151 WAS EPG5 SLC25A22 DYNC2I2 XIAP SLC35A1 GNPTAB TK2 MS4A1 IFNGR1 LEPR CRKL CIITA NPM1 ZMYND10 COL6A2 ATM RNF168 GAS2L2 CDCA7 PRPS1 EHMT1 ERF NHLRC1 TBX6 MUC5B VPS13A RFX5 ASAH1 DNAH5 HYDIN FCGR3A RELB ADAMTS3 SCN9A TTC12 SH2D1A PTPN22 LEP CYBA PGM3 IL17RA MKRN3 NOS1 AFF4 ERCC2 SDCCAG8 IFIH1 CD79B TBC1D24 CHD7 GATA2 POLE LRRC6 TERC TNFRSF13B TAP2 CFTR OFD1 WASHC5 RANBP2 IL7R MYL2 TRAIP CCDC22 IGH CCDC40 IL2RG SNORD116-1 ALOX12B NFKB1 STING1 NCF2 TRPS1 SGCG PARN CHAT TSC1 TBL2 CTCF ACTA1 CACNA1B UBB PIK3CD PEPD DNAAF3 TTC25 CARD11 DNAAF2 CXCR4 MASP2 IL6ST TBC1D24 DRC1 TBCD TCF3 CYBB PIK3R1 SMN1 RSPH3 COG4 TNFSF12 CSPP1 KIF20A USP9X NHP2 HYDIN NBN PYROXD1 CASP8 IL7R SCNN1G CCDC114 TNFSF12 BTK SPINK5 BLNK CD55 IDUA USB1 SIK1 FLNA CLEC7A MAP3K20 KPTN RFX5 FAT4 DKC1 KDM6A IDUA POLA1 TRIP11 PGM3 GUSB DNAH11 KRAS
Protein Mutations 1
H275Y
SNP 0